Clinical response to the CHAPRR protocol in refractory livedoid vasculopathy
a case report
DOI:
https://doi.org/10.47456/rbps.v26i1.51190Keywords:
Livedoid Vasculopathy, Livedo Reticularis, Summer Ulceration, White AtrophyAbstract
Introduction: Livedoid vasculopathy is a chronic and recurrent thrombo-occlusive vascular disease of the distal lower limbs and feet that can lead to the formation of ulcers. Connective tissue diseases, antiphospholipid antibody syndrome, systemic vasculitis and neoplasms may be associated. Treatment is challenging, as the pathophysiology of the lesions involves multiple mechanisms. Case report: we report the case of a middle-aged woman diagnosed with livedoid vasculopathy, a clinical condition that is difficult to manage, with remission of skin lesions after the introduction of the CHAPRR regimen (calcium channel blocker, hydroxycloquine, AAS, pentoxifylline, rivaroxaban and Rituximab). Conclusion: As it is a rare entity, there is no defined consensus on its treatment, therefore the relevance of the topic exemplified in this case report is emphasized.
Downloads
References
Rujitharanawong C, Chularojanamontri L, Trakanwittayarak S, Pinkaew S, Nuttawong S. Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature. Dermatol Ther. 2021 Jan;34(1):e14569. doi: 10.1111/dth.14569. Epub 2020 Nov 29. PMID: 33219608.
Micieli R, Alavi A. Treatment for Livedoid Vasculopathy: A Systematic Review. JAMA Dermatol. 2018 Feb 1;154(2):193-202. doi: 10.1001/jamadermatol.2017.4374. PMID: 29141075.
Coromilas AJ, Micheletti RG. A novel combination (“CHAP”) regimen for management of livedoid vasculopathy in 12 patients. J Am Acad Dermatol. 2023 Mar;88(3):672-674. doi: 10.1016/j.jaad.2022.06.1188. Epub 2022 Jul 1. PMID: 35787412.
Freitas TQ, Halpern I, Criado PR. Livedoid vasculopathy: a compelling diagnosis. Autops Case Rep. 2018 Jul 30;8(3):e2018034. doi: 10.4322/acr.2018.034. PMID: 30101138; PMCID: PMC6066260.
Eswaran H, Googe P, Vedak P, Marston WA, Moll S. Livedoid vasculopathy: A review with focus on terminology and pathogenesis. Vasc Med. 2022 Dec;27(6):593-603. doi: 10.1177/1358863X221130380. Epub 2022 Oct 26. PMID: 36285834; PMCID: PMC9732787.
Sopeña B, Pérez-Rodríguez MT, Rivera A, Ortiz-Rey JA, Lamas J, Freire-Dapena MC. Livedoid vasculopathy and recurrent thrombosis in a patient with lupus: seronegative antiphospholipid syndrome? Lupus. 2010 Oct;19(11):1340-3. doi: 10.1177/0961203310373783. Epub 2010 Jul 21. PMID: 20659971.
Gao Y, Jin H. Livedoid vasculopathy and peripheral neuropathy: A retrospective cohort study of 55 Chinese patients and literature review. Int Wound J. 2023 May;20(5):1498-1505. doi: 10.1111/iwj.14004. Epub 2022 Nov 4. PMID: 36333819; PMCID: PMC10088820.
Hu SC, Chen GS, Lin CL, Cheng YC, Lin YS. Características dermatoscópicas da vasculopatia livedóide. Medicina (Baltimore). Março de 2017; 96(11):e6284. DOI: 10.1097/MD.00000000000006284. PMID: 28296736.
Kumar A, Sharma A, Agarwal A. Livedoid vasculopathy presenting with leg ulcers. Rheumatology (Oxford). 2019 Nov 1;58(11):2076. doi: 10.1093/rheumatology/kez126. PMID: 31220328.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Revista Brasileira de Pesquisa em Saúde (RBPS) adopts the CC BY 4.0 license, which means that authors retain the copyright of the works they submit to the journal. Authors are responsible for declaring that their contribution is an original manuscript, that it has not been previously published, and that it is not under simultaneous review by another scientific journal. Upon submitting the manuscript, authors grant RBPS the exclusive right of first publication, subject to peer review.
Authors are permitted to enter into additional contracts for the non-exclusive distribution of the version published by RBPS (for example, in institutional repositories or as a book chapter), provided that due acknowledgment of authorship and of initial publication by RBPS is given. Authors are also encouraged to make their work available online (for example, in institutional repositories or on their personal pages) after its initial publication in the journal, with due acknowledgment of authorship and of the original publication by RBPS.
Accordingly, under the CC BY 4.0 license, readers have the right to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially;
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
